USPTO Examiner TURKOWSKI KAYLA MARIE - Art Unit 3783

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18674045DRUG DELIVERY DEVICE FOR DELIVERING AT LEAST ONE DRUG, OPTIONALLY AT LEAST ONE RECONSTITUTED DRUG, MEDICAL DEVICE AND MEDICAL SYSTEMMay 2024March 2026Allow2240YesNo
18014566DOSE SETTING SENSOR ASSEMBLY WITH ALGORITHMIC AUTO CALIBRATIONJanuary 2023January 2026Abandon3601NoNo
17954840SAFETY CAPSeptember 2022January 2026Allow4011YesNo
17878403NEEDLE INSERTION MECHANISM FOR AN INJECTION DEVICE WITH AN IMPROVED IMPACT RESISTANCEAugust 2022March 2026Allow4311YesNo
17764828PATIENT-MAINTAINED SEDATIONMarch 2022February 2026Abandon4720YesNo
17627008SEALING ARRANGEMENT FOR DRUG DELIVERY DEVICEJanuary 2022March 2026Abandon5021NoNo
17574127Vascular Access Instrument Advancement Devices, Systems, and MethodsJanuary 2022September 2025Allow4540NoNo
17626012STATE DETECTOR ARRANGEMENT FOR STATE DETECTION OF A MEDICAMENT DELIVERY DEVICEJanuary 2022November 2025Abandon4611NoNo
17570566Probe Delivery Device to Facilitate Advancement of a Probe Within an Intravenous CatheterJanuary 2022July 2025Allow4211YesNo
17569965WEARABLE DRUG DELIVERY DEVICE WITH REMOVAL ELEMENTJanuary 2022August 2025Allow4341YesNo
17557924Fluid Path Optimization in Catheter Insertion SystemsDecember 2021December 2024Allow3630YesYes
17551278INTRAVENOUS CANNULADecember 2021October 2025Allow4650YesNo
17596457Method And Device For Substance Delivery To The Inner EarDecember 2021December 2025Abandon4811NoNo
17547804Wire and Catheter Organizer for Endovascular ProcedureDecember 2021May 2025Allow4150YesNo
17540805LOW DEADSPACE SYRINGE INCLUDING A PIVOTING NEEDLE GUARDDecember 2021July 2025Abandon4310NoNo
17532921RADIOPAQUE MARKER AND DELIVERY SYSTEMNovember 2021April 2025Allow4140YesYes
17531326DRUG DELIVERY DEVICE INCLUDING RESERVOIR WITH FLEXIBLE LININGNovember 2021October 2025Allow4741NoNo
17520425CONNECTORS FOR PERITONEAL DIALYSISNovember 2021May 2025Allow4240YesNo
17609058DEVICES FOR STORAGE AND DELIVERY OF NONPATHOGENIC MICROORGANISMSNovember 2021May 2025Abandon4310NoNo
17519295ANTISEPTIC CONNECTOR COVER AND METHOD OF USENovember 2021April 2024Abandon2901NoNo
17506579SURGICAL HANDPIECE WITH ROTATABLE CANNULA HEADOctober 2021October 2025Abandon4811YesNo
17601917CUTANEOUS DEVICE FOR STORING AND RELEASING MOLECULES, AND CORRESPONDING METHODOctober 2021December 2025Abandon5021NoNo
17492607MONITOR, AND METHOD FOR COMBINED DISPLAY OF PHYSIOLOGICAL SIGN PARAMETERS AND MEDICATION INFORMATION FOR SAMEOctober 2021January 2026Allow5130YesNo
17492103FLUID DELIVERY DEVICE HAVING MULTIPLE PENETRATING ELEMENTSOctober 2021July 2025Allow4502NoNo
17593507FINE NEEDLE INJECTION THERAPY DEVICESeptember 2021February 2025Abandon4101NoNo
17479862MULTI-CHANNEL AUTOMATIC INFUSION CONTROL DEVICESeptember 2021May 2024Abandon3210NoNo
17477821INJECTION DEVICE WITH A CAP FOR REMOVING A NEEDLE SHIELD CAP FROM A PRODUCT CONTAINER, AND METHOD FOR ASSEMBLING SUCH AN INJECTION DEVICESeptember 2021November 2024Allow3810NoNo
17593214FLUSHING VAGINAL STENT DEVICES AND RELATED SYSTEMS AND METHODSSeptember 2021September 2025Abandon4820NoNo
17432581Applicator for Microneedle PatchAugust 2021September 2025Abandon4921NoNo
17408336CATHETER ASSEMBLYAugust 2021August 2025Allow4821YesNo
17432096DRUG INFUSION DEVICEAugust 2021July 2025Allow4720YesNo
17404455INSULIN DELIVERY ARRANGEMENT AND METHOD FOR INSULIN DOSINGAugust 2021March 2025Allow4330YesNo
17310184ASSISTED MANUAL INJECTION DEVICE FOR INJECTING A COMPOSITION CONTAINED IN A CONTAINERJuly 2021July 2025Abandon4820NoNo
17375382PERICARDIAL PUNCTURE DEVICE AND METHODJuly 2021March 2025Allow4420YesNo
17374213MODULAR ADMINISTRATION APPLIANCEJuly 2021May 2025Allow4620YesNo
17417419PORTABLE PUMP FOR DRUG INFUSION THROUGH A SYRINGE REMOVABLY ENGAGED IN THE PUMPJune 2021September 2025Allow5130YesNo
17415956NEEDLELESS INJECTORJune 2021August 2025Allow5030YesNo
17414720Balloon Occlusion CatheterJune 2021March 2026Allow5740YesNo
17413607MECHANISMS FOR PREVENTING RECONNECTION OF CONNECTORS INTENDED FOR SINGLE USEJune 2021November 2024Abandon4101NoNo
17311194Drug Delivery Device and Drug Delivery SystemJune 2021March 2025Abandon4511NoNo
17336912DEFAULT CARBOHYDRATE CONSUMPTION COUNTS BASED ON POPULATION CARBOHYDRATE CONSUMPTION MODELSJune 2021August 2025Allow5030YesNo
17298773MYOCARDIAL PROTECTION SYSTEMJune 2021May 2025Allow4820YesNo
17207416CATHETERIZATION APPARATUS, CATHETER, AND METHODMarch 2021October 2024Abandon4301NoNo
17273084CONNECTION MEMBER, INJECTION DEVICE AND PUMP CASING EQUIPPED WITH CONNECTION MEMBER, AND LIQUID VERIFICATION METHOD USING CONNECTION MEMBERMarch 2021November 2024Allow4521NoNo
17185645METHOD AND DEVICES FOR RECEIVING A CANNULAFebruary 2021September 2024Allow4311YesNo
17270373MEDICAL DEVICE COMPRISING AN ACTUATION ELEMENTFebruary 2021April 2025Allow4930NoNo
17270126MEDICAL INFUSION SYSTEMFebruary 2021September 2025Abandon5550NoNo
17270177Improved Metering Mechanism and Injection DeviceFebruary 2021March 2025Allow4930YesNo
17266513SYSTEM, DEVICE, AND METHOD FOR VASCULAR ACCESSFebruary 2021January 2025Abandon4821NoNo
17266423MEDICATION DELIVERY DEVICE WITH DOSE DETECTION SYSTEMFebruary 2021April 2025Allow5131NoNo
17263478ADMINISTRATION SYSTEM COMPRISING AN ADMINISTRATION DEVICE AND A PROTECTIVE DEVICE PROVIDED WITH A CLOSURE MEMBRANEJanuary 2021August 2024Abandon4310NoNo
17149398SYSTEM AND METHOD FOR DETECTING ISSUES IN THE BASAL RATE IN INSULIN TREATED DIABETES PATIENTSJanuary 2021July 2025Allow5430YesNo
17260400Cartridge Assembly for a Drug Delivery Device and Drug Delivery DeviceJanuary 2021September 2024Allow4421NoNo
17259532SYSTEMS AND METHODS FOR PROVIDING DISTAL EMBOLIC PROTECTIONJanuary 2021December 2025Abandon5931NoNo
17258785Cartridge Unit for a Drug Delivery DeviceJanuary 2021November 2024Allow4621YesNo
17258699CARTRIDGE ASSEMBLY AND METHOD FOR ASSEMBLING THE SAMEJanuary 2021August 2024Allow4421NoNo
17257644PORTABLE AUTO INJECTION APPARATUS WITH SHORT LENGTHJanuary 2021June 2024Abandon4110NoNo
17256568CHEMICAL LIQUID INJECTING APPARATUSDecember 2020August 2025Allow5640YesNo
17256214EPIDURAL DELIVERY DEVICEDecember 2020August 2025Abandon5630NoNo
16972587Improvements in, or relating to, applicatorsDecember 2020June 2024Allow4220NoNo
16972511SAFETY CAPDecember 2020December 2025Allow6051YesNo
17056125SENSOR ASSEMBLY WITH IDENTIFIER DETERMINATIONNovember 2020February 2026Allow6041NoYes
17045840Universal Single-Use Cap For Male And Female ConnectorsOctober 2020February 2025Allow5240YesNo
17045817Medical Injection SystemOctober 2020January 2024Allow4010NoNo
16976102INTRAVASCULAR PORT BASED SENSING AND TREATMENT SYSTEMAugust 2020May 2024Abandon4410NoNo
16603543CHEMICAL LIQUID INJECTOROctober 2019August 2024Allow5920NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner TURKOWSKI, KAYLA MARIE.

Strategic Value of Filing an Appeal

Total Appeal Filings
3
Allowed After Appeal Filing
1
(33.3%)
Not Allowed After Appeal Filing
2
(66.7%)
Filing Benefit Percentile
55.5%
Higher than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 33.3% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.

Strategic Recommendations

Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.

Examiner TURKOWSKI, KAYLA MARIE - Prosecution Strategy Guide

Executive Summary

Examiner TURKOWSKI, KAYLA MARIE works in Art Unit 3783 and has examined 56 patent applications in our dataset. With an allowance rate of 62.5%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 47 months.

Allowance Patterns

Examiner TURKOWSKI, KAYLA MARIE's allowance rate of 62.5% places them in the 23% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by TURKOWSKI, KAYLA MARIE receive 2.29 office actions before reaching final disposition. This places the examiner in the 64% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by TURKOWSKI, KAYLA MARIE is 47 months. This places the examiner in the 10% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.

Interview Effectiveness

Conducting an examiner interview provides a +58.3% benefit to allowance rate for applications examined by TURKOWSKI, KAYLA MARIE. This interview benefit is in the 96% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 34.2% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 15.8% of cases where such amendments are filed. This entry rate is in the 17% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 200.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 99% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences are highly effective with this examiner compared to others. Before filing a full appeal brief, strongly consider requesting a PAC. The PAC provides an opportunity for the examiner and supervisory personnel to reconsider the rejection before the case proceeds to the PTAB.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 99% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 120.0% are granted (fully or in part). This grant rate is in the 95% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 47% percentile). This examiner makes examiner's amendments less often than average. You may need to make most claim amendments yourself.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.7% of allowed cases (in the 82% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Plan for RCE after final rejection: This examiner rarely enters after-final amendments. Budget for an RCE in your prosecution strategy if you receive a final rejection.
  • RCEs are effective: This examiner has a high allowance rate after RCE compared to others. If you receive a final rejection and have substantive amendments or arguments, an RCE is likely to be successful.
  • Request pre-appeal conferences: PACs are highly effective with this examiner. Before filing a full appeal brief, request a PAC to potentially resolve issues without full PTAB review.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Plan for extended prosecution: Applications take longer than average with this examiner. Factor this into your continuation strategy and client communications.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.